[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641116":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":27,"studyPopulation":28,"armGroups":29,"interventions":35,"overallOfficials":17,"centralContacts":39,"locations":48,"responsibleParty":63,"collaborators":17,"id":67,"slug":17,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":17,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":17,"enrollmentInfo":74,"targetDuration":77,"studyType":78,"phases":17,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":51,"whyStopped":17,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Fudan University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":12,"otherOutcomes":17},[9],{"measure":10,"description":10,"timeFrame":11},"The incidence of cancer-related fatigue (CRF) in tumor patients.","Baseline",[13,15,18,20,22],{"measure":14,"description":14,"timeFrame":11},"The severity grading of cancer-related fatigue (CRF) in tumor patients across different tumor types and multiple treatment settings.",{"measure":16,"description":17,"timeFrame":11},"The correlation between treatment regimen and the incidence of cancer-related fatigue (CRF).",null,{"measure":19,"description":17,"timeFrame":11},"The incidence of anti-tumor treatment delays, dose reductions, or regimen modifications due to cancer-related fatigue (CRF).",{"measure":21,"description":17,"timeFrame":11},"Progression-free survival (PFS) and overall survival (OS) in patients with different grades of cancer-related fatigue (CRF) undergoing anti-tumor therapy.",{"measure":23,"description":17,"timeFrame":11},"To assess the state and severity of cancer-related fatigue (CRF) in patients with malignant tumors using the Brief Fatigue Inventory - Cancer (BFI-C) and the Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF).",{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":25,"timePerspective":26,"maskingInfo":17},"COHORT","CROSS_SECTIONAL","This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis. Using patient-completed questionnaires, combined with outpatient visit records and telephone follow-up, this study will explore the following aspects:\n\nAssess the incidence and severity of cancer-related fatigue in patients with malignant tumors.\n\nAnalyze the influencing factors of cancer-related fatigue, including tumor type, treatment regimen, disease stage, efficacy of anti-tumor therapy, adverse events associated with anti-tumor therapy, and concomitant medications.\n\nEvaluate the impact of cancer-related fatigue on anti-tumor treatment and prognosis.\n\nAssess the multidimensional state and severity of cancer-related fatigue in patients with malignant tumors using the Brief Fatigue Inventory - Cancer (BFI-C) and the Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF).\n\nBy collecting patients' medical information, including imaging and laboratory results, as well as outpatient and telephone follow-up records, this study will explore the following aspects:\n\nEvaluate the impact of different degrees of cancer-related fatigue on the prognosis of patients with malignant tumors.\n\nExplore the impact of the efficacy of anti-tumor therapy on the multidimensional state and severity of cancer-related fatigue in patients.","Patients with malignant tumors in various tumor types and multiple treatment scenarios.",[30],{"label":31,"type":17,"description":32,"interventionNames":33},"Patients with malignant tumors","1. Male or female, aged 18 years or older.\n2. Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form.\n3. Malignant tumor confirmed histologically or cytologically.",[34],"Other: No Interventions",[36],{"type":6,"name":37,"description":37,"armGroupLabels":38,"otherNames":17},"No Interventions",[31],[40,45],{"name":41,"role":42,"phone":43,"phoneExt":17,"email":44},"Hongxia Wang, PhD","CONTACT","021-33988888","whx365@126.com",{"name":46,"role":42,"phone":43,"phoneExt":17,"email":47},"Juan Jin, PhD","medjinjuan@126.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":17},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":58,"coordinates":59},"Point",[60,61],121.45806,31.22222,{"lat":61,"lon":60},{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Hongxia Wang","Pro","100641116",false,"NCT07656324","Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue","Inclusion Criteria:\n\n1. Male or female, aged 18 years or older.\n2. Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form.\n3. Malignant tumor confirmed histologically or cytologically.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study.\n3. Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma).\n4. Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses.\n5. Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure.\n6. Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.","ALL","18 Years",{"count":75,"type":76},1000000,"ESTIMATED","2 Years","OBSERVATIONAL","This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis.",[81],"Cancer",[83,81],"Fatigue","2026-06-15",{"date":86,"type":87},"2026-06-18","ACTUAL",{"date":89,"type":87},"2025-01-17",{"date":91,"type":76},"2027-01-17",{"name":5,"class":6},1]